866-997-4948(US-Canada Toll Free)

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Head and Neck Cancer

No. of Pages : 203 Pages

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

 

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Content

 

 

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Head And Neck Cancer Squamous Cell Carcinoma Overview 8
Therapeutics Development 9
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview 9
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 10
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 11
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 14
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 19
Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 21
Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 22
Boehringer Ingelheim GmbH 22
F. Hoffmann-La Roche Ltd. 23
Shionogi & Co., Ltd. 24
Amgen Inc. 25
Sanofi 26
AstraZeneca PLC 27
Eli Lilly and Company 28
GlaxoSmithKline plc 29
MedImmune, LLC 30
Celltrion, Inc. 31
Novartis AG 32
Eisai Co., Ltd. 33
ImmunoGen, Inc. 34
Nanobiotix SA 35
Acceleron Pharma, Inc. 36
Virttu Biologics Limited 37
Ascenta Therapeutics, Inc. 38
Jennerex Biotherapeutics, Inc. 39
Onconova Therapeutics, Inc. 40
Viventia Biotechnologies Inc. 41
Oncovir, Inc. 42
Gliknik, Inc. 43
Tolero Pharmaceuticals, Inc. 44
AlphaMab Co., Ltd 45
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 53
Assessment by Route of Administration 58
Assessment by Molecule Type 61
Drug Profiles 64
cetuximab - Drug Profile 64
gefitinib - Drug Profile 71
afatinib - Drug Profile 76
nimorazole - Drug Profile 79
curcumin - Drug Profile 81
dalantercept - Drug Profile 82
pemetrexed disodium - Drug Profile 84
everolimus - Drug Profile 90
rigosertib sodium - Drug Profile 94
oportuzumab monatox - Drug Profile 97
LY-2606368 - Drug Profile 99
Dendritic Cell Vaccine - Drug Profile 100
pazopanib hydrochloride - Drug Profile 102
LY-2801653 - Drug Profile 106
GL-0810 - Drug Profile 107
GL-0817 - Drug Profile 108
Poly-ICLC - Drug Profile 109
golvatinib - Drug Profile 111
AT-406 - Drug Profile 113
EGFR Antisense DNA Therapy - Drug Profile 116
BYL-719 - Drug Profile 117
GSK-2636771 - Drug Profile 119
S-488210 - Drug Profile 120
vandetanib - Drug Profile 121
JX-929 - Drug Profile 127
NBTXR-3 - Drug Profile 128
imgatuzumab - Drug Profile 130
cabazitaxel - Drug Profile 132
LJM-716 - Drug Profile 134
GC-4419 - Drug Profile 135
HSV-1716 - Drug Profile 136
MEDI-4736 - Drug Profile 137
interleukin-15 - Drug Profile 138
IMGN-289 - Drug Profile 140
T4 Immunotherapy - Drug Profile 141
Recombinant Adenoviral Human p53 Gene Therapy - Drug Profile 142
GSK-2849330 - Drug Profile 143
raltegravir potassium + [cisplatin] - Drug Profile 144
cetuximab biosimilar - Drug Profile 145
Anti-CD-147 Antibody - Drug Profile 146
Pactamycin Analogs - Drug Profile 148
Antibody to Inhibit FRMD4A for Oncology - Drug Profile 149
LOXL4 Monoclonal Antibody - Drug Profile 150
cetuximab biosimilar - Drug Profile 151
AZ-64 - Drug Profile 152
cetuximab biosimilar - Drug Profile 153
MV-NIS Vaccine - Drug Profile 154
SHetA-2 - Drug Profile 156
SGI-7079 - Drug Profile 157
Inhibitors of Cancer Stem Cells - Drug Profile 158
ESX-Med23 Inhibitor - Drug Profile 159
Withanolide Derivatives - Drug Profile 160
Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 162
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 189
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 190
Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 191
Featured News & Press Releases 191
 

Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 199
Disclaimer 199

List of Table

 

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2014 13

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2014 14

Number of Products under Development by Companies, H1 2014 16

Number of Products under Development by Companies, H1 2014 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H1 2014 19

Comparative Analysis by Late Stage Development, H1 2014 20

Comparative Analysis by Clinical Stage Development, H1 2014 21

Comparative Analysis by Early Stage Development, H1 2014 22

Products under Development by Companies, H1 2014 23

Products under Development by Companies, H1 2014 (Contd..1) 24

Products under Investigation by Universities/Institutes, H1 2014 25

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 26

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 27

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H1 2014 28

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H1 2014 29

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sanofi, H1 2014 30

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca PLC, H1 2014 31

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2014 32

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline plc, H1 2014 33

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H1 2014 34

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion, Inc., H1 2014 35

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H1 2014 36

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2014 37

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by ImmunoGen, Inc., H1 2014 38

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Nanobiotix SA, H1 2014 39

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2014 40

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H1 2014 41

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ascenta Therapeutics, Inc., H1 2014 42

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Jennerex Biotherapeutics, Inc., H1 2014 43

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H1 2014 44

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Biotechnologies Inc., H1 2014 45

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncovir, Inc., H1 2014 46

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H1 2014 47

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 48

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AlphaMab Co., Ltd, H1 2014 49

Assessment by Monotherapy Products, H1 2014 50

Assessment by Combination Products, H1 2014 51

Number of Products by Stage and Target, H1 2014 54

Number of Products by Stage and Mechanism of Action, H1 2014 59

Number of Products by Stage and Route of Administration, H1 2014 64

Number of Products by Stage and Molecule Type, H1 2014 67

Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2014 166

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H1 2014 193

Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H1 2014 194

List of Chart

 

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2014 13

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2014 14

Number of Products under Development by Companies, H1 2014 15

Number of Products under Investigation by Universities/Institutes, H1 2014 18

Comparative Analysis by Late Stage Development, H1 2014 20

Comparative Analysis by Clinical Stage Development, H1 2014 21

Comparative Analysis by Early Stage Products, H1 2014 22

Assessment by Monotherapy Products, H1 2014 50

Number of Products by Top 10 Target, H1 2014 52

Number of Products by Stage and Top 10 Target, H1 2014 53

Number of Products by Top 10 Mechanism of Action, H1 2014 57

Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 58

Number of Products by Top 10 Route of Administration, H1 2014 62

Number of Products by Stage and Top 10 Route of Administration, H1 2014 63

Number of Products by Top 10 Molecule Type, H1 2014 65

Number of Products by Stage and Top 10 Molecule Type, H1 2014 66

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *